The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes
Systemic metabolic syndrome significantly increases the risk of morbidity and mortality in
patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis …
patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis …
TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase
S Xu, X Wu, S Wang, M Xu, T Fang… - The Journal of …, 2024 - Am Soc Clin Investig
Nonalcoholic fatty liver disease (NAFLD) encompasses a disease continuum from simple
steatosis to nonalcoholic steatohepatitis (NASH). However, there are currently no approved …
steatosis to nonalcoholic steatohepatitis (NASH). However, there are currently no approved …
[PDF][PDF] The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis
FJ Yan, XJ Zhang, WX Wang, YX Ji, PX Wang… - …, 2017 - Wiley Online Library
Tripartite motif 8 (TRIM8), an E3 ligase ubiquitously expressed in various cells, is closely
involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely …
involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely …
Loss of TRIM67 attenuates the progress of obesity-induced non-alcoholic fatty liver disease
C Huang, X Wei, Q Luo, Y Xia, T Pan, J He… - International Journal of …, 2022 - mdpi.com
Obesity is considered as a major cause for the development and progress of non-alcoholic
fatty liver disease (NAFLD), which is one of the most prevalent chronic liver diseases …
fatty liver disease (NAFLD), which is one of the most prevalent chronic liver diseases …
[HTML][HTML] Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1
L Wang, X Zhang, ZB Lin, PJ Yang, H Xu, JL Duan… - Cell Metabolism, 2021 - cell.com
Nonalcoholic steatohepatitis (NASH)-related hepatocellular carcinoma and liver disorders
have become the leading causes for the need of liver transplantation in developed …
have become the leading causes for the need of liver transplantation in developed …
Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4
GN Zhao, P Zhang, J Gong, XJ Zhang, PX Wang… - Nature medicine, 2017 - nature.com
Non-alcoholic steatohepatitis (NASH) is an increasingly prevalent liver pathology that can
progress from non-alcoholic fatty liver disease (NAFLD), and it is a leading cause of cirrhosis …
progress from non-alcoholic fatty liver disease (NAFLD), and it is a leading cause of cirrhosis …
The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin‐Mediated Degradation of 3‐Hydroxy‐3‐Methylglutaryl CoA Reductase …
Q Yang, X Chen, Y Zhang, S Hu, F Hu, Y Huang… - …, 2021 - Wiley Online Library
Background and Aims NAFLD is the most prevalent chronic liver disease worldwide, but no
effective pharmacological therapeutics are available for clinical use. NASH is the more …
effective pharmacological therapeutics are available for clinical use. NASH is the more …
[PDF][PDF] Ring finger protein20 regulates hepatic lipid metabolism through protein kinase A‐dependent sterol regulatory element binding protein1c degradation
JH Lee, GY Lee, H Jang, SS Choe, SH Koo… - Hepatology, 2014 - Wiley Online Library
Sterol regulatory element binding protein1c (SREBP1c) is a key transcription factor for de
novo lipogenesis during the postprandial state. During nutritional deprivation, hepatic …
novo lipogenesis during the postprandial state. During nutritional deprivation, hepatic …
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
J Zhang, H Xie, J Yao, W Jin, H Pan, Z Pan, D Xie… - Human Cell, 2023 - Springer
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease around the
world. However, no specific medicine has been approved for NAFLD treatment. Our study …
world. However, no specific medicine has been approved for NAFLD treatment. Our study …
TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice
S Jiang, LC Minter, SA Stratton, P Yang, HA Abbas… - Journal of …, 2015 - Elsevier
Background & Aims Aberrantly high expression of TRIM24 occurs in human cancers,
including hepatocellular carcinoma. In contrast, TRIM24 in the mouse is reportedly a liver …
including hepatocellular carcinoma. In contrast, TRIM24 in the mouse is reportedly a liver …